Search

everythinglearnresearchcommunity

for

Search:↓

PRP treatment increased hair density, especially in men and younger patients with AGA.

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

The laser treatment improved hair appearance and was safe and well-received by patients.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

The treatment was not recommended due to limited effectiveness and significant side effects.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

The method effectively showed that the two exemestane preparations are bioequivalent.

Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.

Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.

Oral baricitinib is effective and safe for treating alopecia areata.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Low-level light therapy safely improves hair coverage, thickness, and count in androgenetic alopecia patients.

Compound 3 protects the heart from damage by activating A1-adenosine receptors.

Both lasers are equally effective and safe for treating freckles.

Bicalutamide improved hair growth more than spironolactone in women with hair loss.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.

Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.

Splitting non-scored tablets can lead to uneven drug distribution, posing risks.

The combination therapy was effective and well-tolerated, especially in young patients.

The treatment slightly increased hair growth and was safe for most women.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.